Abstract
Missing data are frequent in Alzheimers disease (AD) trials due to the age of participants and the nature of the disease. This can lead to bias and decreased statistical power. We assessed the level and causes of missing data in a 2-year randomised trial of an AD patient management program (PLASA study), and conducted sensitivity analyses on the primary endpoint (functional decline), using various methods for handling missing data: complete case, LOCF, Z-score LOCF, longitudinal mixed effects model, multiple imputation. By 2 years, 32% of the 1131 subjects had dropped out, with the commonest reasons being death (28% of dropouts) and refusal (22%). Baseline cognitive and functional status were predictive of dropout. All sensitivity analyses led to the same conclusion: no effect of the intervention on the rate of functional decline. All analyses demonstrated significant functional decline over time in both groups, but the magnitude of decline and between-group (intervention versus usual care) differences varied across methods. In particular, the LOCF analysis substantially underestimated 2-year decline in both groups compared to other methods. Our results suggest that data were not “missing completely at random”, meaning that the complete case method was unsuitable. The LOCF method was also unsuitable since it assumes no decline after dropout. Methods based on the more plausible “missing at random” hypothesis (multiple imputation, longitudinal mixed effects models, z-score LOCF) appeared more appropriate. This work highlights the importance of considering the validity of the underlying hypotheses of methods used for handling missing data in AD trials.
Keywords: Alzheimer's disease, randomised controlled trials, clinical trial methodology, missing data, dropout, data interpretation, statistical methods, Cox regression, ADCS-ADL, MAR assumption
Current Alzheimer Research
Title: How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients?
Volume: 8 Issue: 4
Author(s): N. Coley, V. Gardette, C. Cantet, S. Gillette-Guyonnet, F. Nourhashemi, B. Vellas and S. Andrieu
Affiliation:
Keywords: Alzheimer's disease, randomised controlled trials, clinical trial methodology, missing data, dropout, data interpretation, statistical methods, Cox regression, ADCS-ADL, MAR assumption
Abstract: Missing data are frequent in Alzheimers disease (AD) trials due to the age of participants and the nature of the disease. This can lead to bias and decreased statistical power. We assessed the level and causes of missing data in a 2-year randomised trial of an AD patient management program (PLASA study), and conducted sensitivity analyses on the primary endpoint (functional decline), using various methods for handling missing data: complete case, LOCF, Z-score LOCF, longitudinal mixed effects model, multiple imputation. By 2 years, 32% of the 1131 subjects had dropped out, with the commonest reasons being death (28% of dropouts) and refusal (22%). Baseline cognitive and functional status were predictive of dropout. All sensitivity analyses led to the same conclusion: no effect of the intervention on the rate of functional decline. All analyses demonstrated significant functional decline over time in both groups, but the magnitude of decline and between-group (intervention versus usual care) differences varied across methods. In particular, the LOCF analysis substantially underestimated 2-year decline in both groups compared to other methods. Our results suggest that data were not “missing completely at random”, meaning that the complete case method was unsuitable. The LOCF method was also unsuitable since it assumes no decline after dropout. Methods based on the more plausible “missing at random” hypothesis (multiple imputation, longitudinal mixed effects models, z-score LOCF) appeared more appropriate. This work highlights the importance of considering the validity of the underlying hypotheses of methods used for handling missing data in AD trials.
Export Options
About this article
Cite this article as:
Coley N., Gardette V., Cantet C., Gillette-Guyonnet S., Nourhashemi F., Vellas B. and Andrieu S., How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients?, Current Alzheimer Research 2011; 8 (4) . https://dx.doi.org/10.2174/156720511795745339
DOI https://dx.doi.org/10.2174/156720511795745339 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Targeting Tau Hyperphosphorylation <I>via</I> Kinase Inhibition: Strategy to Address Alzheimer's Disease
Current Topics in Medicinal Chemistry Alzheimers Disease - An Interactive Perspective
Current Alzheimer Research Psychological Treatments for Cognitive Dysfunction in Major Depressive Disorder: Current Evidence and Perspectives<sup>§</sup>
CNS & Neurological Disorders - Drug Targets Tribute to Prof. Gerald Farin: Remembering A Geometric Modeling Researcher and Educator
Neuroscience and Biomedical Engineering (Discontinued) Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research A Review: Natural Compounds as Anti-Alzheimer´s Disease Agents
Current Nutrition & Food Science Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research 3D-QSAR and Molecular Docking Studies of Flavonoid Derivatives as Potent Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Human Disease and Drug Pharmacology, Complex as Real Life
Current Medicinal Chemistry